Comparing the current results to its competitors, Allarity Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.94 %, recorded in the same quarter.
Allarity Therapeutics Inc , slower than the average decrease reported by the company's competitors of -82.09 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -82.09 %
Allarity Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment alongside large pharmaceutical and biotechnology firms, academic institutions, government agencies, and other research organizations engaged in cancer therapy research, development, manufacturing, and commercialization. It develops small molecules, drug conjugates, and companion diagnostics for cancer treatment. Named competitors include AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme (Sanofi), and Roche. These competitors often possess greater financial resources and expertise in drug development and commercialization. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors, while smaller or early-stage companies also present competition.
February 24, 2025
Boston (February 24, 2025) In an exciting development for oncology research, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced the initiation of enrollment for a new Phase 2 clinical trial protocol focused on its innovative treatment, stenoparib. Targeted toward patients suffering from advanced ovarian cancer, this trial signifies a significant step forward in advancing stenoparib toward potential FDA approval. Stenoparib represents a groundbreaking approach as a differentiated dual inhibitor targeting both the PARP and Wnt pathways, which are critical in cancer development and progression. The company is leveraging its proprietary patient selection...
November 18, 2024
Allarity Therapeutics, Inc. a Boston-based clinical-stage pharmaceutical company focused on developing personalized cancer treatments, has recently reported significant advancements in its Phase 2 trial of stenoparib, a PARP inhibitor designed to target specific cancer types. On November 18, 2024, the company unveiled critical updates including an extended treatment duration for patients in the ongoing trial, a bolstered cash position that supports plans for a follow-up FDA registrational trial, and new revenue-generating opportunities stemming from its laboratory services.The company’s Phase 2 trial has showcased promising results, which could pave the way for substantive regulatory approvals and wider ...
November 6, 2024
In a significant development within the pharmaceutical sector, Bragar Eagel and Squire, P.C. a prominent stockholder rights law firm, has announced the initiation of a class action lawsuit against Allarity Therapeutics, Inc. (NASDAQ: ALLR). The lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who bought or otherwise acquired Allarity securities during the defined period from May 17, 2022, to July 19, 2024. This timeframe constitutes the Class Period, and concerned investors are encouraged to contact the firm for further information.According to the law firm s release, investors have until November 12, 2024, to apply to ...
September 24, 2024
Understanding the Landscape: Class Action Lawsuit and Executive Changes at Allarity Therapeutics In the fast-paced world of biotechnology, investor sentiments are often swayed by corporate maneuvers and legal challenges. Recent developments surrounding Allarity Therapeutics, Inc. (NASDAQ: ALLR) highlight how these elements can intertwine, significantly affecting the company s future. 1. Class Action Lawsuit Announcement On September 24, 2024, Rosen Law Firm a prominent player in global investor rights announced the filing of a class action lawsuit on behalf of investors in Allarity Therapeutics. This lawsuit concerns shareholders who purchased securities between May 17, 2022, and July 19, 2024, and sets a de...
September 16, 2024
In the grand tapestry of medical science, wherein every thread constitutes the ceaseless pursuit of knowledge and advancement, recent pronouncements from Allarity Therapeutics render a noteworthy addition. The firm hath disclosed that two esteemed patients, subjects of a noble trial employing Stenoparib, have transcended the notable threshold of one year whilst undergoing treatment for advanced ovarian cancer. This remarkable feat not only contributes to the annals of therapeutic efficacy but also heralds a potential paradigmatic shift in the management of malignant afflictions.Stenoparib, an innovative pharmacological intervention, emerged from the diligent inquiries into the mechanisms underlying malignanc...
July 24, 2024
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company committed to revolutionizing personalized cancer treatments, is appealing to its esteemed stockholders to actively engage in the forthcoming annual meeting of stockholders on July 26, 2024. This crucial event marks a pivotal moment in Allarity s journey towards maximizing its potential in the pharmaceutical industry. The company is steadfast in its pursuit of innovative solutions that address the challenges faced by cancer patients worldwide and offers a brighter future for those affected by this devastating disease.Optimizing Growth: The Reverse Stock Split ProposalOne of the key topics to be discussed at the annual ...
June 27, 2024
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company focused on developing personalized cancer treatments, has recently demonstrated remarkable resilience and strategic adaptability. In a series of noteworthy developments, the company has made significant strides towards re-establishing and maintaining NASDAQ compliance, alongside reporting promising clinical outcomes in their Phase 2 trials. This article delves into Allarity Therapeutics’ journey through financial compliance challenges, clinical trial achievements, and the strategic maneuvers that underscore its dedication to bringing personalized oncological therapies to the market. The biopharmaceutical landscape...
June 25, 2024
Allarity Therapeutics Stenoparib Demonstrates Prolonged Clinical Benefits in Advanced Ovarian Cancer, Company Achieves Nasdaq Compliance and Strong Financial GrowthConclusionAllarity Therapeutics Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer has exhibited compelling results, with multiple patients experiencing extended treatment durations exceeding 30 weeks. This achievement showcases the potential of stenoparib as an effective personalized cancer treatment for patients with recurrent ovarian cancerFurthermore, the company s strong financial performance and achievement of Nasdaq compliance validate its position as a leading player in the oncology sector. Allarity Therapeutics ...
May 20, 2024
Allarity Therapeutics Meets Nasdaq s Minimum Stockholders Equity Requirement, Demonstrating Financial Stability in its Pursuit of Personalized Cancer TreatmentsBoston, May 20, 2024 - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company at the forefront of developing personalized cancer treatments, is pleased to announce that it has regained compliance with Nasdaq s minimum stockholders equity requirement. The Company received formal written notice from The Nasdaq Stock Market, LLC s Office of General Counsel, affirming their compliance with the Equity Rule as outlined in Nasdaq Listing Rule 5550(b)(1).This achievement reflects Allarity Therapeutics steadfast commitme...
May 14, 2024
Allarity Therapeutics Achieves Clear Clinical Benefits in Early Conclusion of Phase 2 Trial for Advanced Ovarian Cancer, Regains NASDAQ Compliance, and Boosts Cash and Equity BalancesBoston (May 2, 2024) - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company specializing in personalized cancer treatments, announced today the successful early termination of its Phase 2 clinical trial for stenoparib, a groundbreaking PARP inhibitor, in the treatment of advanced recurrent ovarian cancer. This decision was made based on the clear clinical benefits observed in the enrolled patients who had been pre-screened using Allarity s Drug Response predictor (DRP) companion diagnostic (CDx), e...
Publicly Traded Peers of Allarity Therapeutics Inc
Sunshine Biopharma Inc Share Performance
-11.98%
30 Days
Sunshine Biopharma Inc
Profile
Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.
PTC Therapeutics Inc's business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.
Puretech Health Plc is a biotechnology company that operates a unique business model focusing on innovation and entrepreneurship. They identify and validate disruptive technologies and build and invest in companies around those technologies, with a focus on identifying unmet medical needs. By developing a diversified portfolio of cutting-edge healthcare companies, Puretech aims to deliver breakthrough therapies to improve patient outcomes.
Prothena Corporation Public Limited Company Share Performance
-8.54%
Over The Past 5 Days
Prothena Corporation Public Limited Company
Profile
Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.
Sources:
Allarity Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Allarity Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
